Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Accured Expenses (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Change in Accured Expenses for 15 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 52.72% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $364000.0, a 111.15% increase, with the full-year FY2025 number at $886000.0, up 109.67% from a year prior.
  • Change in Accured Expenses was $3.5 million for Q4 2025 at Aytu Biopharma, up from -$1.6 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $8.0 million in Q1 2023 to a low of -$14.5 million in Q2 2022.
  • A 5-year average of -$706210.5 and a median of $164000.0 in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: crashed 574.67% in 2022, then soared 879.88% in 2025.
  • Aytu Biopharma's Change in Accured Expenses stood at -$3.9 million in 2021, then skyrocketed by 162.73% to $2.5 million in 2022, then plummeted by 48.52% to $1.3 million in 2023, then soared by 474.23% to $7.3 million in 2024, then tumbled by 52.72% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Change in Accured Expenses are $3.5 million (Q4 2025), -$1.6 million (Q3 2025), and -$3.1 million (Q2 2025).